Osteosarcoma Clinical Trial Pipeline Expands as 25+ Companies Driving Innovation in the Therapeutics | DelveInsight

DelveInsight's "Osteosarcoma Pipeline Insight 2025" report provides comprehensive insights about 25+ companies and 30+ pipeline drugs in Othe steosarcoma pipeline landscape. It covers the Osteosarcoma pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Osteosarcoma pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Download our comprehensive report now to explore clinical-stage developments and strategic collaborations transforming the industry! @ https://www.delveinsight.com/sample-request/osteosarcoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Key Takeaways from the Osteosarcoma Pipeline Report
• On February 05, 2026- Merck Sharp & Dohme LLC conducted a study is to assess the efficacy and safety of zilovertamab vedotin in pediatric participants with relapsed or refractory B-cell acute lymphoblastic leukemia (B-ALL), diffuse large B-cell lymphoma (DLBCL)/Burkitt lymphoma, or neuroblastoma and in pediatric and young adult participants with Ewing sarcoma.
• On February 03, 2026- Jazz Pharmaceuticals announced a study is conducted in two phases. The phase 1 portion of the study evaluates the safety, tolerability, pharmacokinetics (PK), recommended phase 2 dose (RP2D), and effectiveness of lurbinectedin monotherapy in pediatric participants with previously treated solid tumors. This is followed by the phase 2 portion, to further assess the effectiveness and safety in pediatric and young adult participants with recurrent/refractory Ewing sarcoma.
• DelveInsight's Osteosarcoma pipeline report depicts a robust space with 25+ active players working to develop 30+ pipeline therapies for Osteosarcoma treatment.
• The leading Osteosarcoma Companies such as Zentalis Pharmaceuticals, MedPacto, Salarius Pharmaceuticals, NextPoint Therapeutics, Base Therapeutics, EMD Serono, Hansoh BioMedical R&D, Cellectar Biosciences, OS Therapies, AlaMab Therapeutics, and others.
• Promising Osteosarcoma Therapies such as Olaparib, Ceralasertib, Vactosertib, Avelumab, ZN-c3, Gemcitabine and others.

Learn how leading Osteosarcoma Companies are positioning themselves for success in the evolving pharmaceutical market-access the full report today!" @ https://www.delveinsight.com/sample-request/osteosarcoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Osteosarcoma Emerging Drugs Profile
• HS-20093: Hansoh BioMedical R&D Company
HS-20093 is a novel B7-H3-targeted antibody-drug conjugate that consists of a fully humanized anti-B7-H3 monoclonal antibody covalently linked to a topoisomerase inhibitor (TOPOi) payload. This innovative drug is being developed for the treatment of lung cancer, sarcoma, head and neck cancers, and other solid tumors through multiple phase I and II clinical trials in China. The mechanism of action (MOA) of HS-20093 involves the specific targeting of B7-H3, a transmembrane receptor highly prevalent on malignant cells, with the monoclonal antibody component. This targeting allows for the delivery of the topoisomerase inhibitor payload directly to the cancer cells, where it can exert its cytotoxic effects, potentially leading to tumor cell death and inhibition of tumor growth. Currently, the drug is in Phase II stage of its clinical trial for the treatment of Osteosarcoma.

• ZN c3: Zentalis Pharmaceuticals
ZN-c3 is a combination with gemcitabine used in adult and pediatric subjects with relapsed or refractory osteosarcoma. ZN-c3 is a phase I/II drug, developed by Zentalis Pharmaceuticals. ZN-c3 drug is an investigational drug and gemcitabine is an approved drug. ZN-c3 have received a fast track designation for uterine cancer but is under phase I/II for osteosarcoma.

• NPX267: Nextpoint Therapeutics
NPX267 is a first-in-class monoclonal antibody targeting KIR3DL3, the inhibitory receptor for the HHLA2 pathway (B7-H7), and is designed to prevent immune escape in solid tumors. By blocking the binding of KIR3DL3 on exhausted T and NK cells to HHLA2 expressed on tumor cells, NPX267 may be able to reactivate tumor antigen-primed immune cells in HHLA2-expressing solid tumors. Preventing KIR3DL3-mediated immune suppression may enhance anti-tumor immune responses for patients with HHLA2-positive cancers - a tumor antigen expressed independently of PD-L1. Currently, the drug is in Phase I stage of its clinical trial for the treatment of Osteosarcoma.

The Osteosarcoma pipeline report provides insights into
• The report provides detailed insights about companies that are developing therapies for the treatment of Osteosarcoma with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Osteosarcoma Treatment.
• Osteosarcoma Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Osteosarcoma Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Osteosarcoma market.

From early-stage research to late-phase Osteosarcoma Clinical Trials, our analysis covers key Osteosarcoma Companies, innovative treatment approaches, and the next wave of Emerging Drugs- Download now! @ https://www.delveinsight.com/sample-request/osteosarcoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Osteosarcoma Companies
Zentalis Pharmaceuticals, MedPacto, Salarius Pharmaceuticals, NextPoint Therapeutics, Base Therapeutics, EMD Serono, Hansoh BioMedical R&D, Cellectar Biosciences, OS Therapies, AlaMab Therapeutics, and others.

Osteosarcoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as,
• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical

Osteosarcoma Products have been categorized under various Molecule types such as
• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy

Stay updated with the latest Osteosarcoma Pipeline Insights-download our report for a deep dive into the next generation of therapeutics! @ https://www.delveinsight.com/sample-request/osteosarcoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the Osteosarcoma Pipeline Report
• Coverage- Global
• Osteosarcoma Companies- Zentalis Pharmaceuticals, MedPacto, Salarius Pharmaceuticals, NextPoint Therapeutics, Base Therapeutics, EMD Serono, Hansoh BioMedical R&D, Cellectar Biosciences, OS Therapies, AlaMab Therapeutics, and others.
• Osteosarcoma Therapies- Olaparib, Ceralasertib, Vactosertib, Avelumab, ZN-c3, Gemcitabine and others.
• Osteosarcoma Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Osteosarcoma Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Find answers in our latest Osteosarcoma Pipeline Insights report, featuring in-depth coverage of Clinical Trials, regulatory trends, and upcoming breakthroughs @ https://www.delveinsight.com/sample-request/osteosarcoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Content
1. Introduction
2. Executive Summary
3. Osteosarcoma: Overview
4. Osteosarcoma Pipeline Therapeutics
5. Osteosarcoma Therapeutic Assessment
6. Osteosarcoma - DelveInsight's Analytical Perspective
7. Late Stage Products (Phase III)
8. Drug name: Company name
9. Drug profiles in the detailed report.....
10. Mid Stage Products (Phase II)
11. HS-20093: Hansoh BioMedical R&D Company
12. Drug profiles in the detailed report.....
13. Early Stage Products (Phase I/II)
14. NPX267: Nextpoint Therapeutics
15. Drug profiles in the detailed report.....
16. Inactive Products
17. Osteosarcoma Key Companies
18. Osteosarcoma Key Products
19. Osteosarcoma- Unmet Needs
20. Osteosarcoma- Market Drivers and Barriers
21. Osteosarcoma- Future Perspectives and Conclusion
22. Osteosarcoma Analyst Views
23. Osteosarcoma Key Companies
24. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: ybhardwaj@delveinsight.com
Phone: 09650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

This release was published on openPR.